WNT inhibitory factor-1 (WIF1) is an antagonist of the WNT signaling pathway. We investigated the relationship between WIF1 promoter methylation and regulation of the WNT/b-catenin signaling pathway, tumor grade, and survival in patients with astrocytoma. This study included 86 cases of astrocytoma, comprising 20 diffuse astrocytomas and 66 glioblastomas. In addition, 17 temporal lobectomy specimens from patients with epilepsy were included as controls. The ratio of methylated DNA to total methylated and unmethylated DNA (% methylation) was measured by methylation-and unmethylation-specific PCR. Representative tumor tissue was immunostained for WIF1, b-catenin, cyclin D1, c-myc, and isocitrate dehydrogenase 1. Levels of WIF1 promoter methylation, mRNA expression, and protein expression in a glioblastoma cell line were compared before and after demethylation treatment. The mean percent methylation of the WIF1 promoter in astrocytomas was higher than that in control brain tissue. WIF1 protein expression was lower in the tumor group with 45% methylation than in the group with o5% methylation. Cytoplasmic b-catenin staining was more frequently observed in tumors with a low WIF1 protein expression level. Demethylation treatment of a glioblastoma cell line increased WIF1 mRNA and protein expression. Increased WIF1 promoter methylation and decreased WIF1 protein expression were not related to patient survival. In conclusion, WIF1 expression is downregulated by promoter methylation and is an important mechanism of aberrant WNT/b-catenin pathway activation in astrocytoma pathogenesis. Modern Pathology (2013) 26, 626-639; doi:10.1038/modpathol.2012.215; published online 18 January 2013Keywords: astrocytoma; b-catenin; glioblastoma; promoter methylation; WNT inhibitory factor-1; WNT pathway Astrocytomas are the most common primary tumors of the central nervous system. Despite aggressive treatment with surgery and subsequent chemoradiotherapy, high-grade astrocytomas show a high rate of recurrence and mortality. 1 Understanding the molecular basis of astrocytoma tumorigenesis is necessary for prediction of therapy response, prognosis, and the development of more effective therapies. Recently, several reports showed a relationship between the WNT signaling pathway and the grade and prognosis of astrocytomas. [2][3][4] Both mRNA and protein expression levels of b-catenin are increased in astrocytoma compared with normal brain tissue. 4 They are also higher in high ¼ grade tumors than in low-grade tumors. 2,4 Moreover, cytoplasmic/nuclear b-catenin and